Pharmaceutical News

RSS

EvoGenix expands capabilities through US acquisition

EvoGenix and Absalus own complementary technologies which, when combined, are capable of streamlining the identification of new antibody drug candidates and improving the development of safe and effective human therapeutic antibodies.

4 Apr 2005

Australia gets a Jumbo online pharmacy

Australian Jumbo Corporation Limited (JUM) has announced an aggresive move into the online pharmacy business with the public release of the JumboPharmacy website.

4 Apr 2005

Ranbaxy settles NHS generic drug claim

Britain's Department of Health and Ranbaxy (UK) Ltd have jointly announced settlement of the claims brought against Ranbaxy for alleged anti-competitive cartel conduct in connection with the supply to the NHS of generic drugs between 1996 and 2000.

4 Apr 2005

Meth abuse and curbs on cold medicines

As states and Congress rush to put common cold, cough and allergy drugs behind the pharmacy counter to curb illegal methamphetamine production, no one has asked consumers what they think about these restrictions -- until now. Harris Interactive asked nearly 3,000 consumers about these and related issues in a national survey commissioned by the National Consumers League (NCL) and Food Marketing Institute (FMI).

4 Apr 2005

New ion channel drug targets to emerge in pharmaceutical discovery

The identification and structural determination of channel proteins, and their validation as therapeutic targets using high throughput cell based and multiplexed screening technologies, have furnished an increase role for ion channel targets in the drug discovery and development pipelines in the pharmaceutical and biotechnology industries.

4 Apr 2005

Tarvacin shows significant anti-viral activity

Peregrine Pharmaceuticals today announced that there will be two presentations, April 4 and 6, at the American Association of Immunologists (AAI) annual meeting in San Diego, California, indicating the anti-viral potential of its Tarvacin antibody. Dr. Melina Soares of The University of Texas Southwestern Medical Center at Dallas will present pre-clinical data titled "Targeting inside-out phospholipids on viruses in a guinea pig model of Lassa fever."

4 Apr 2005

$2.6 million complaint filed against Illinois by British Ecosse Hospital Products

Gov. Rod Blagojevich of Illinois has had a legal complaint demanding nearly $2.6 million filed against him by a British wholesaler Ecosse Hospital Products Ltd. for 254,250 doses of a flu vaccine ordered by Blagojevich to provide thousands of flu vaccine doses for Illinois.

4 Apr 2005

New once a day asthma treatment approved by FDA

More than 5,000 people die from asthma each year in the United States. Although asthma deaths are infrequent, they have increased significantly during the last two decades.

4 Apr 2005

HHS awards $97 million contract to Sanofi Pasteur to speed the production process for new influenza vaccines

United States Department of Health and Human Services has awarded a $97 million contract to Sanofi Pasteur to speed the production process for new influenza vaccines for the U.S.

3 Apr 2005

New drug approved for treating endometriosis

Drug manufacturer Pfizer announced today that the U.S. Food and Drug Administration (FDA) has given approval for the release of depo-subQ provera 104 to be prescribed for the management of pain associated with endometriosis, a gynecological condition that affects one in ten women of reproductive age.

30 Mar 2005

Construction will enable pSivida to increase BrachySil production

Global nanotechnology company pSivida Limited has announced that it's UK manufacturing partner, Atomising Systems Ltd ("ASL"), has reached a key milestone in the manufacture of BrachySil, its lead product, by completing construction of a state of the art dedicated cleanroom facility to GMP specifications at its Sheffield plant in the United Kingdom. ASL is a world leader in high temperature atomising technology.

30 Mar 2005

New drug to treat chronic hepatitis B

The U.S. Food and Drug Administration (FDA) has given approval for a new drug to treat the potentially life-threatening disease Chronic hepatitis B.

30 Mar 2005

Ranbaxy to appeal injunction against sales of Quinapril

Ranbaxy Laboratories Limited (Ranbaxy) announced today that the U.S. District Court for the District of New Jersey hearing the preliminary injunction motion brought by Pfizer against Teva Pharmaceuticals USA, Inc. (Teva) and Ranbaxy Pharmaceuticals Inc. (RPI) enjoined Teva and RPI from selling RPI's quinapril tablets (5, 10, 20, and 40 mg).

30 Mar 2005

REPLICor to disclose unique antiviral drug

REPLICor Inc., a privately owned biopharmaceutical company, is developing a broad spectrum antiviral drug called REP 9 which has the broadest spectrum of activity in vitro ever reported for a single chemical entity.

30 Mar 2005

Favorable Austrian ruling for Ranbaxy on Atorvastatin

Ranbaxy Pharmaceuticals, Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Ltd (Ranbaxy), hasy announced that it successfully invalidated claims 1-3 (all claims sought to be invalidated) of Austrian Patent No. AT E 207 896 as anticipated by, and as lacking inventive step over, respectively, a Pfizer-owned published patent application and a Pfizer owned patent, as reflected by a decision released by the Austrian Patent Office.

30 Mar 2005

Pfizer awarded injunction blocking Teva/Ranbaxy from selling generic Quinapril

Pfizer Inc has obtained a preliminary injunction halting sales of a generic quinapril product marketed by Teva Pharmaceuticals USA Inc., Ranbaxy Pharmaceuticals Inc., and Ranbaxy Laboratories Limited.

30 Mar 2005

Pharmaceutical reproductive rights in the United States

The battle over reproductive rights in the United States has taken another turn with some pharmacists refusing to fill prescriptions for birth control and morning-after pills on the grounds that dispensing the medications violates their moral or religious beliefs.

29 Mar 2005

Onconase granted orphan drug status for malignant mesothelioma in Australia

Alfacell Corporation has announced that the Therapeutic Goods Administration (TGA) in Australia has granted Onconase (ranpirnase) Orphan Drug status for the indication of malignant mesothelioma (MM). Onconase is also designated as an Orphan Drug for MM in Europe.

28 Mar 2005

US tendency to arrogantly flout international ethical practice for patient trials abroad

The US Food and Drug Administration (FDA) has proposed that observing a widely accepted code of medical ethics that protects patients who take part in trials is not necessary for studies conducted abroad, states a comment in this week’s issue of The Lancet.

28 Mar 2005

India passes the drug Patent Bill

India's parliament passed a new law Wednesday, the Patent (Amendment) Bill, prohibiting the copying of patented drugs, despite strong criticism that the legislation would prohibit the manufacture of low-cost generic drugs.

23 Mar 2005